T lymphocyte therapy of cancer

Physiological Research

Volumn 53, Issue 5, 2004, Pages 463-469

  Michälek, Jaroslav ^a,b,c   Buchler T ^c   Hajek R ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Cancer; T lymphocyte; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL ADHESION; CELL KILLING; CELL MIGRATION; CELL SURVIVAL; CELL SUSPENSION; CELL TRANSFER; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNOBLASTIC LYMPHOMA; IMMUNOGENICITY; LEUKEMIA; LYMPHOCYTE CLONE; LYMPHOCYTIC INFILTRATION; MELANOMA; MOLECULAR RECOGNITION; PROTEIN TARGETING; SHORT SURVEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 8444226785     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (34)

1. ALEXANDER-MILLER MA, LEGGATT GR, BERZOFSKY JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93: 4102-4107, 1996.
2. BARNES DWH, CORP MJ, LOUTIT JF, NEAL FE: Treatment of murine leukaemia with X-rays and homologous bone marrow. Preliminary communication. Br Med J 2: 626-627, 1956.
3. BEN-EFRAIM S: Cancer immunotherapy: hopes and pitfalls. Anti-cancer Res 16: 3235-3240, 1996.
4. BRODIE SJ, LEWINSOHN DA, PATTERSON BK, JIYAMAPA D, KRIEGER J, COREY L, GREENBERG PD, RIDDELL SR: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med 5: 34-41, 1999.
5. COHEN PA, PENG L, KJAERGAARD J, PLAUTZ GE, FINKE JH, KOSKI GK, CZERNIECKI BJ, SHU S: T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 21: 215-248, 2001.
6. DUDLEY ME: Cell transfer therapy: basic principles and preclinical studies. In: Principles and Practice of the Biologic Therapy of Cancer. SA ROSENBERG (ed), Lippincott Williams and Wilkins, Philadelphia, 2000, pp 305-321.
7. DUDLEY ME, WUNDERLICH J, NISHIMURA MI, YU D, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ, HWU P, MARINCOLA FM, SHERRY R, LEITMAN SF, ROSENBERG SA: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24: 363-373, 2001.
8. FIGLIN RA, PIERCE WC, KABOO R, TSO CL, MOLDAWER N, GITLITZ B, DEKERNION J, BELLDEGRUN A: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CDS+ selected tumor infiltrating lymphocytes from primary tumor. J Urol 158: 740-745, 1997.
9. GERAGHTY PJ, MULE JJ: Genetically modified lymphocytes and hematopoietic stem cells as therapeutic vehicles. In: Gene Therapy in the Treatment of Cancer. BE HUBER, I MAGRATH (eds), Cambridge University Press, London, 1998, pp 137-148.
10. + T cell adoptive immunotherapy. Immunity 13: 265-276, 2000.
11. JAGER E, RINGHOFFER M, ALTMANNSBERGER M, ARAND M, KARBACH J, JAGER D, OESCH F, KNUTH A: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71: 142-147, 1997.
12. KAMMULA US, MARINCOLA FM: Cancer immunotherapy: is there real progress at last? Biodrugs 11: 249-260, 1999.
13. KOLB HJ, SCHATTENBERG A, GOLDMAN JM, HERTENSTEIN B, JACOBSEN N, ARCESE W, LJUNGMAN P, FERRANT A, VERDONCK L, NIEDERWIESER D: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041-2050, 1995.
14. MUSIANI P, MODESTI A, GIOVARELLI M, CAVALLO F, COLOMBO MP, LOLLINI PL, FORNI G: Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 18: 32-36, 1997.
15. PEGGS KS, MACKINNON S: Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol 8: 349-354, 2001.
16. RENKVIST N, CHIARA C, PAUL FR, GIORGIO P: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2000.
17. RIDDELL SR, GREENBERG PD: T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 45: 35-43, 2000.
18. RIDDELL SR, GREENBERG PD: Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13: 545-586, 1995.
19. RIDDELL SR, GREENBERG PD: Cellular adoptive immunotherapy after bone marrow transplantation. Cancer Treat Res 76: 337-369, 1995.
20. ROONEY CM, SMITH CA, NG CYC, LOFTIN SK, SIXBEY JW, GAN Y, SRIVASTAVA DK, BOWMAN LC, KRANCE RA, BRENNER MK, HESLOP HE: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555, 1998.
21. ROSENBERG SA, AEBERSOLD P, CORNETTA K, KASID A, MORGAN RA, MOEN R, KARSON EM, LOTZE MT, YANG JC, TOPALIAN SL: Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578, 1990.
22. ROSENBERG SA, YANNELLI JR, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ, WEBER JS, PARKINSON DR, SEIPP CA, EINHORN JH, WHITE DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86: 1159-1166, 1994.
23. ROSKROW MA, SUZUKI N, GAN Y, SIXBEY JW, NG CY, KIMBROUGH S, HUDSON M, BRENNER MK, HESLOP HE, ROONEY CM: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91: 2925-2934, 1998.
24. SAHIN U, TURECI O, SCHMITT H, COCHLOVIUS B, JOHANNES T, SCHMITS R, STENNER F, LUO G, SCHOBERT I, PFREUNDSCHUH M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813, 1995.
25. SHILYANSKY J, YANG JC, CUSTER MC, SPIESS PJ, MIXON A, COLE DJ, MULE JJ, ROSENBERG SA, NISHIMURA MI: Identification of a T-cell receptor from a therapeutic murine T-cell clone. J Immunother 20: 247-255, 1997.
26. SLAVIN S: Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol 2: 491-498, 2001.
27. STANCOVSKI I, SCHINDLER DG, WAKS T, YARDEN Y, SELA M, ESHHAR Z: Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151: 6577-6582, 1993.
28. STAVELEY-O'CAROLL K, SOTOMAYOR E, MONTGOMERY J, BORELL L, HWANG L, FEIN S, PARDOLL D, LEVITSKY H: Induction of antigen-specific T-cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95: 1178-1183, 1998.
29. THEOBALD M, RUPPERT T, KUCKELKORN U, HERNANDEZ J, HAUSSLER A, FERREIRA EA, LIEWER U, BIGGS J, LEVINE AJ, HUBER C, KOSZINOWSKI UH, KLOETZEL PM, SHERMAN LA: The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 188: 1017-1028, 1998.
30. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P, LURQUIN C, DE PLAEN E, VAN DER EYNDE B, KNUTH A, BOON T: A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
31. VAN DEN EYNDE BJ, VAN DEN BRUGGEN P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
32. WEIS GR, MARGOLIN KA, ARONSON FR, SZNOL M, ATKINS MB, DUTCHER JP, GAYNOR ER, BOLDT DH, DOROSHOW JH, BAR MH: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10: 275-281, 1992.
33. WALTER EA, GREENBERG PD, GILBERT MJ, FINCH RJ, WATANABE KS, THOMAS ED, RIDDELL SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044, 1995.
34. WEIDEN PL, FLOURNEY N, THOMAS ED, PRENTICE R, FEFER A, BUCKNER CD, STORE R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068-1073, 1979.